Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function
- 12 November 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 20 (2) , 185-196
Abstract
Type 1 diabetes (T1D) is a chronic autoimmune endocrinopathy with increasing incidence that results in the depletion of pancreatic beta cells and exogenous insulin dependence. Despite technological advances in insulin delivery, disease control remains suboptimal, while previous immunotherapy options have failed to prevent T1D. Recently, teplizumab, an immunomodulating monoclonal antibody, was approved to delay or prevent T1D. Five randomized controlled trials have tested different regimens of administration, mostly 14-day schemes with dose escalation. In participants with new-onset T1D, teplizumab delayed C-peptide decline, improved glycemic control, and reduced insulin demand for a median of 1 or 2 years. Studies in at-risk relatives of patients showed a decrease in T1D incidence during 2 years of follow-up. Subgroups of responders with unique metabolic and immunological characteristics were identified. Mild to moderate adverse effects were reported, including transient rash, cytopenia, nausea, vomiting, and infections. Teplizumab marks a turning point in T1D therapy. Areas of future research include the ideal population for screening, cost-effectiveness, and challenges in treatment accessibility. More studies are essential to evaluate the ideal duration of the regimen, the potential benefit of combinations with other drugs, and to identify endophenotypes with a high probability of response.Keywords
This publication has 61 references indexed in Scilit:
- B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year ResultsDiabetes Care, 2014
- Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive childrenDiabetologia, 2013
- C-Peptide Response and HLA Genotypes in Subjects With Recent-Onset Type 1 Diabetes After Immunotherapy With DiaPep277Diabetes, 2011
- Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Young Children Participating in Longitudinal Follow-UpDiabetes Care, 2011
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Becoming self-aware: the thymic education of regulatory T cellsCurrent Opinion in Immunology, 2011
- Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 DiabetesDiabetes Care, 2010
- Challenges in developing endpoints for type 1 diabetes intervention studiesDiabetes/Metabolism Research and Reviews, 2009
- Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral InfectionImmunity, 2007
- THE NOD MOUSE: A Model of Immune DysregulationAnnual Review of Immunology, 2005